Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Antimicrob Agents Chemother ; 46(4): 977-81, 2002 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-11897578

RESUMO

T-705 (6-fluoro-3-hydroxy-2-pyrazinecarboxamide) has been found to have potent and selective inhibitory activity against influenza virus. In an in vitro plaque reduction assay, T-705 showed potent inhibitory activity against influenza A, B, and C viruses, with 50% inhibitory concentrations (IC(50)s) of 0.013 to 0.48 microg/ml, while it showed no cytotoxicity at concentrations up to 1,000 microg/ml in Madin-Darby canine kidney cells. The selectivity index for influenza virus was more than 2,000. It was also active against a neuraminidase inhibitor-resistant virus and some amantadine-resistant viruses. T-705 showed weak activity against non-influenza virus RNA viruses, with the IC(50)s being higher for non-influenza virus RNA viruses than for influenza virus, and it had no activity against DNA viruses. Orally administered T-705 at 100 mg/kg of body weight/day (four times a day) for 5 days significantly reduced the mean pulmonary virus yields and the rate of mortality in mice infected with influenza virus A/PR/8/34 (3 x 10(2) PFU). These results suggest that T-705 may be a compound that is useful and highly selective against influenza virus infections and that has a mode of action different from those of commercially available drugs, such as amantadine, rimantadine, and neuraminidase inhibitors.


Assuntos
Amidas/farmacologia , Amidas/uso terapêutico , Antivirais/farmacologia , Antivirais/uso terapêutico , Influenza Humana/tratamento farmacológico , Orthomyxoviridae/efeitos dos fármacos , Pirazinas/farmacologia , Pirazinas/uso terapêutico , Animais , Linhagem Celular , Ensaios de Seleção de Medicamentos Antitumorais , Humanos , Influenza Humana/virologia , Pulmão/virologia , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Testes de Sensibilidade Microbiana , Vírus/efeitos dos fármacos
2.
Eur J Pharmacol ; 348(1): 45-51, 1998 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-9650830

RESUMO

Kakkon-to is composed of seven medicinal herbs and exhibited novel antipyretic activity by suppressing interleukin-1alpha production responsive to interferon in a murine intranasal influenza virus infection model. Using this model, antipyretic compounds with such novel biological activities were characterized from the herbs. The organic solvent-extractable fractions of Cinnamomum cassia among the herbs showed antipyretic activity. We selected six antipyretic compounds from 48 cinnamyl derivatives and related compounds that may be mainly involved in the fractions. Their antipyretic activity was significantly correlated with interleukin-1alpha regulatory activity. Four of them suppressed interleukin-1alpha production to a basal level and showed different mode of antipyretic action from that of aspirin in interleukin-1alpha-injected mice. Structure-bioactivity relationship of the four suggested that an ester bond played an important role for both antipyretic and interleukin-1alpha regulatory activities. These compounds may be useful in analyzing interleukin-1alpha-producing cells in fever production and the mechanism of defervescence by suppressing interferon-induced interleukin-1alpha production.


Assuntos
Analgésicos não Narcóticos/farmacologia , Cinamatos/farmacologia , Vírus da Influenza A , Infecções por Orthomyxoviridae/fisiopatologia , Animais , Aspirina/farmacologia , Feminino , Febre/tratamento farmacológico , Febre/etiologia , Interleucina-1/metabolismo , Camundongos , Camundongos Endogâmicos DBA , Plantas Medicinais/química , Relação Estrutura-Atividade
3.
Am J Gastroenterol ; 92(4): 703-4, 1997 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-9128330

RESUMO

Although herbal medicines are believed to be safe with few side effects, there are several reports on drug-induced liver injury caused by them. However, there are no reports of autoimmune hepatitis triggered by herbal medicines. We report here the case of a patient with autoimmune hepatitis that became clinically apparent after administration of Dai-saiko-to (Da-Chai-Hu-Tang), an herbal medicine that is used as a standard medicine in Japan.


Assuntos
Doenças Autoimunes/induzido quimicamente , Doença Hepática Induzida por Substâncias e Drogas/etiologia , Medicamentos de Ervas Chinesas/efeitos adversos , Doenças Autoimunes/diagnóstico , Doenças Autoimunes/tratamento farmacológico , Doença Hepática Induzida por Substâncias e Drogas/diagnóstico , Doença Hepática Induzida por Substâncias e Drogas/tratamento farmacológico , Combinação de Medicamentos , Fígado Gorduroso/complicações , Fígado Gorduroso/tratamento farmacológico , Feminino , Glucocorticoides/uso terapêutico , Hepatite Crônica/complicações , Hepatite Crônica/tratamento farmacológico , Humanos , Pessoa de Meia-Idade , Prednisolona/uso terapêutico
4.
Gan To Kagaku Ryoho ; 22(11): 1665-8, 1995 Sep.
Artigo em Japonês | MEDLINE | ID: mdl-7574788

RESUMO

We presented two patients with post-Lip-TAE biloma resulting in portal occlusion, and reviewed 20 previous studies including our cases to investigate their clinical characteristics. Case 1. A 31-year-old woman suffered from an HCC located at the S8 segment, and had a superselective embolization of feeding arteries using 3 ml of Lip, 300 mg of CBDCA, and 40 mg of Epi-Adriamycin (Epi-ADM). Eleven weeks later, CT showed multiple cystic lesions, and the percutaneous transhepatic drainages of the lesions were established. At 21 weeks after Lip-TAE, we found occlusion of the right branch of portal vein on CT, but she recovered from this condition, and was discharged 1 year later. Case 2. A 62-year-old man was diagnosed as HCC located at S7-6 segments, and was infused with 3 ml of Lip, 150 mg of CBDCA, and 30 mg of Epi-ADM through a right hepatic artery. Ten weeks later, CT showed a cystic lesion in the S7-8 segments, occlusion of the right anterior segmental branch of the portal vein, and the same drainage was also established. Unfortunately, he died of liver failure 18 weeks later. In the literature, biloma after Lip-TAE occurred at 71.2 mean days, ranging from 7 to 180 days, a with remarkable increase in biliary tree-associated enzymes. Seven (35%) of 20 patients died of liver failure or sepsis during 3 weeks and 1 year, and 3 (60%) of 5 patients accompanied by occlusion of a certain portal branch frequently died. We consider that these patients need intensive care and should be under long follow-up.


Assuntos
Ductos Biliares Intra-Hepáticos , Bile , Carcinoma Hepatocelular/terapia , Quimioembolização Terapêutica/efeitos adversos , Óleo Iodado/efeitos adversos , Neoplasias Hepáticas/terapia , Veia Porta , Trombose/etiologia , Adulto , Doenças dos Ductos Biliares/etiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
5.
Gan To Kagaku Ryoho ; 21(13): 2229-32, 1994 Sep.
Artigo em Japonês | MEDLINE | ID: mdl-7944447

RESUMO

One hundred and eighty-nine patients with hepatocellular carcinoma (HCC) underwent hepatectomy since 1987 to 1992 in our institute. Recurrences were detected on residual liver in 84 patients up to December 1993. Sixty-seven of 84 patients were treated with re-resection (group-O, n = 11), transarterial embolization (TAE) combined with percutaneous ethanol injection therapy (PEIT) (group-TP, n = 13), TAE alone (group-T, n = 34) and intraarterial chemotherapy (group-IA, n = 9). Among these 67 cases, the efficacy of treatment for recurrences was investigated. There was no significant difference in age, positive ratio of hepatitis B virus, ICG R15 and percentage of underlying liver cirrhosis among the 4 groups. However, the frequency of patients with 2 nodules or less, was significantly higher in group-O than in other groups. Cumulative 1-, 2- and 3-year survival rates (%) were 88.9, 64.8 and 51.9 in group-O, 92.1, 55.4 and 55.4 in group-TP, 70.9, 49.6 and 31.0 in group-T, and 16.9, 0 and 0 in group-IA, respectively. The survival rate after recurrences in group-TP was higher than in group-IA and group-T, and almost equivalent to that of group-O. Either re-resection or TAE combined with PEIT might assure- a favorable prognosis in patients with recurrent HCC.


Assuntos
Carcinoma Hepatocelular/terapia , Quimioembolização Terapêutica , Etanol/administração & dosagem , Óleo Iodado/administração & dosagem , Neoplasias Hepáticas/terapia , Recidiva Local de Neoplasia/terapia , Hepatectomia , Artéria Hepática , Humanos , Infusões Intra-Arteriais , Injeções Intralesionais , Pessoa de Meia-Idade , Prognóstico , Estudos Retrospectivos
6.
Gan To Kagaku Ryoho ; 17(8 Pt 2): 1643-7, 1990 Aug.
Artigo em Japonês | MEDLINE | ID: mdl-2167640

RESUMO

A case of double cancer, early gastric cancer and hepatocellular carcinoma, was reported. The patient was diabetic and had liver cirrhosis. After gastrectomy for gastric cancer which was hemorrhagic, he was treated by intra-hepatic arterial infusion chemotherapy followed by hepatic resection. Histopathologically, about half of the main tumor showed necrosis, but very viable new cancer cell nests were seen around the main nodule. The patient is in good condition without recurrence of hepatic lesion 1 year after resection. The usefulness of arterial infusion chemotherapy was demonstrated in the case of double cancer, in which it is difficult to resect both cancers simultaneously.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Carcinoma Hepatocelular/terapia , Hepatectomia , Cirrose Hepática/complicações , Neoplasias Hepáticas/terapia , Neoplasias Primárias Múltiplas , Neoplasias Gástricas , Carcinoma Hepatocelular/cirurgia , Cisplatino/administração & dosagem , Terapia Combinada , Doxorrubicina/administração & dosagem , Gastrectomia , Artéria Hepática , Humanos , Infusões Intra-Arteriais , Óleo Iodado/administração & dosagem , Neoplasias Hepáticas/cirurgia , Masculino , Medroxiprogesterona/administração & dosagem , Medroxiprogesterona/análogos & derivados , Acetato de Medroxiprogesterona , Pessoa de Meia-Idade , Neoplasias Gástricas/cirurgia , Tamoxifeno/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA